Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib.

酪氨酸激酶抑制剂治疗慢性髓系白血病时角化病毛发样萌发 ： 与伊马替尼相关的文献综述和报告。

• 影响指数: 4.964
• 发表时间: 2023 Dec 20
• 来源期刊: J Clin Med
• DOI: 10.3390/jcm13010032
• PMID: 38202039
• 文章类型: Journal Article
• 中科院分区: Q2
• 方向: 医学
• 作者列表: Ambrogio F,Poli MA,Lospalluti L,Lettini T,Cassano N,Vena GA,Ingravallo G,Cazzato G,Foti C

关键词: BCR-ABL; adverse cutaneous reaction; chronic myeloid leukemia; imatinib; keratosis pilaris; molecular targets; tyrosine kinase inhibitors

Abstract

The advent of tyrosine kinase inhibitors (TKIs) blocking BCR-ABL activity has revolutionized the therapeutic management of patients with chronic myeloid leukemia (CML). Adverse cutaneous reactions (ACRs) are common nonhematologic adverse events associated with the use of BCR-ABL TKIs. A characteristic pattern of eruption resembling keratosis pilaris (KP) has been described in patients treated with these drugs, especially nilotinib and dasatinib. The pathogenesis of this ACR is still unknown. This type of reaction appears to be uncommon with imatinib. Here, we report the case of an elderly patient with an asymptomatic KP-like eruption, which appeared one month after starting treatment with imatinib for CML. The case presentation is accompanied by a review of similar reactions in patients with CML treated with BCR-ABL inhibitors, attempting to make an excursus on the molecular targets of such drugs and possible mechanisms underlying this ACR.

摘要

阻断BCR-ABL活性的酪氨酸激酶抑制剂（TKIs）的出现彻底改变了慢性粒细胞白血病（CML）患者的治疗管理。不良皮肤反应（ACRs）是与使用BCR-ABLTKIs相关的常见非血液学不良事件。在用这些药物治疗的患者中，已经描述了类似毛发角化病（KP）的喷发特征模式，尤其是尼洛替尼和达沙替尼。这种ACR的发病机制仍然未知。这种类型的反应似乎是罕见的伊马替尼。这里,我们报告了一个无症状的KP样喷发的老年患者，伊马替尼治疗CML1个月后出现.病例报告伴随着对BCR-ABL抑制剂治疗的CML患者的类似反应的回顾，试图对此类药物的分子靶标和这种ACR的可能机制进行概述。